ArticleInnovations in pharmacy2023

Post-Menopausal Quality of Life Claims: Overlooking the Requirements of Normal Science and Fundamental Measurement in ICER'S Cost-Effectiveness Assessment of Fezolinetant for Moderate to Severe Vasomotor Symptoms.

Paul C LangleyPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.